Roland Ricken1, Sandra Bopp2, Peter Schlattmann3, Hubertus Himmerich4, Tom Bschor5, Christoph Richter6, Thomas J Stamm2, Frank Bauer7, Andreas Heinz2, Rainer Hellweg2, Undine E Lang8, Mazda Adli9. 1. Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany. Electronic address: roland.ricken@charite.de. 2. Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany. 3. Department of statistics, informatics and documentation, Friedrich-Schiller-Universität Jena, Jena, Germany. 4. Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany. 5. Department of Psychiatry, Schlosspark-Klinik Berlin; Berlin, Germany; Department of Psychiatry and Psychotherapy, Technical University of Dresden Medical School, Dresden, Germany. 6. Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany; Department of Psychiatry and Psychotherapy, Vivantes Wenckebach Klinikum, Berlin, Germany. 7. Department of Psychiatry and Psychotherapy, Fliedner Klinik Berlin, Berlin, Germany. 8. Department of Psychiatry and Psychotherapy, University Psychiatric Clinics (UPK), Switzerland. 9. Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany; Department of Psychiatry and Psychotherapy, Fliedner Klinik Berlin, Berlin, Germany.
Abstract
BACKGROUND: Meta-analytical data show lithium augmentation (LA) as an effective treatment strategy in major depression. Weight-gain is a common side effect of LA. The proteohormone leptin is discussed to be involved in the pathophysiology of weight gain induced by psychopharmacological treatment. The purpose of our study was to investigate the association of leptin and body mass index (BMI) during LA in a prospective cohort study. METHODS: Leptin serum concentrations and body mass index (BMI) were measured in a total of 89 acute depressive patients before and then after four weeks of LA. RESULTS: In a linear mixed model analysis the following variables had a significant positive effect on BMI: time (equal with "treatment effect of LA"; F1.83=6.05; p=0.016) and leptin (F1.111=13.83; p=0.0003) as well as the covariates male gender (F1.89=5.08; p=0.027) and adiposity (F1.85=105.13; p<0.0001). LIMITATIONS: If the reported effect of leptin on BMI is specific to LA remains unclear without a control group. CONCLUSION: Leptin signalling might be involved in lithium-induced weight-gain.
BACKGROUND: Meta-analytical data show lithium augmentation (LA) as an effective treatment strategy in major depression. Weight-gain is a common side effect of LA. The proteohormone leptin is discussed to be involved in the pathophysiology of weight gain induced by psychopharmacological treatment. The purpose of our study was to investigate the association of leptin and body mass index (BMI) during LA in a prospective cohort study. METHODS:Leptin serum concentrations and body mass index (BMI) were measured in a total of 89 acute depressivepatients before and then after four weeks of LA. RESULTS: In a linear mixed model analysis the following variables had a significant positive effect on BMI: time (equal with "treatment effect of LA"; F1.83=6.05; p=0.016) and leptin (F1.111=13.83; p=0.0003) as well as the covariates male gender (F1.89=5.08; p=0.027) and adiposity (F1.85=105.13; p<0.0001). LIMITATIONS: If the reported effect of leptin on BMI is specific to LA remains unclear without a control group. CONCLUSION:Leptin signalling might be involved in lithium-induced weight-gain.
Authors: Sandra K Bopp; Urs Heilbronner; Peter Schlattmann; Pichit J Buspavanich; Undine E Lang; Andreas Heinz; Thomas G Schulze; Mazda Adli; Thomas W Mühleisen; Roland Ricken Journal: Eur Neuropsychopharmacol Date: 2021-10-13 Impact factor: 4.600